Ganymed’s IMAB362 Receives Orphan Drug Designation from FDA and EMA

News   Oct 21, 2013

 
Ganymed’s IMAB362 Receives Orphan Drug Designation from FDA and EMA
 
 
 

RELATED ARTICLES

Scientists Report The Development of a Potent New Medicine to Fight Addiction

News

Scientists report the development of a potent new medicine to fight addiction.

READ MORE

Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain Therapeutics

News

The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.

READ MORE

Discovery of Exomeres Could Help Reveal How Cancer Cells Spread

News

A new cellular messenger discovered by Weill Cornell Medicine scientists may help reveal how cancer cells co-opt the body's intercellular delivery service to spread to new locations in the body.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE